PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years
The higher rate of reported post-vaccination symptoms could either be due to a higher susceptibility for symptomatic effects following immune stimulation, or due to a trained awareness to health-related symptoms. The data emphasizes the importance to evaluate safety of the new mRNA COVID-19 vaccines not only in healthy children but also in children with comorbidities. To perform such evaluation should be made mandatory for pharmaceutical enterprises.
Authors
- Sarah Kotsias-Konopelska (ORCID: https://orcid.org/0009-0006-8509-0499)
- Ania C. Muntau (ORCID: https://orcid.org/0000-0002-2900-8378)
- Folke Brinkmann (ORCID: https://orcid.org/0000-0002-4307-4232)
- Nicole Toepfner (ORCID: https://orcid.org/0000-0002-9693-4419)
- Kevin Paul (ORCID: https://orcid.org/0000-0002-0998-4881)
- Reinhard Berner (ORCID: https://orcid.org/0000-0002-6216-9173)
- Maximilian Jorczyk
- Julia Pagel (ORCID: https://orcid.org/0000-0002-8427-0213)
- Anne Schlegtendal (ORCID: https://orcid.org/0000-0002-6737-3624)
- Sarah Holzwarth
- Jochen Schmitt (ORCID: https://orcid.org/0000-0003-0264-0960)
- Svenja Dreßen
- Christoph Maier (ORCID: https://orcid.org/0000-0003-1212-744X)
- Kimiya Saadat
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Infection Research (DE)
- German Center for Lung Research (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Arcadis (Czechia) (CZ)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Infection
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1007/s15010-024-02427-2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00